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Congenital mesoblastic nephroma (CMN) is a rare pediatric renal tumor with low malignant 40 
potential that most commonly occurs early in infancy. Treatment strategies are based on the few 41 
published CMN series, while a significant number of CMN patients have been described in case 42 
reports. The aim of this narrative review was to create an up-to-date overview of the literature. 43 
Complete surgical removal is curative in most cases. The risk of treatment-related mortality 44 
(both surgery- and chemotherapy-related) is relatively high in the first weeks of life, indicating 45 
that these young patients deserve special attention with respect to timing and type of treatment. 46 
47 
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Congenital mesoblastic nephroma (CMN) is a rare tumor with low malignant potential, which 49 
represents approximately 3% of all pediatric renal tumors [1-3]. It is the most common renal 50 
neoplasm diagnosed in the first month of life [4,5]. CMN is frequently recognized before or at 51 
time of birth, illustrating the embryonal character of the disease. 52 
Bolande was the first to use the term ‘congenital mesoblastic nephroma’ in 1967, though decades 53 
earlier this tumor was already described using different terminologies including fetal renal 54 
hamartoma and leiomyomatous renal hamartoma [3,6-9]. The histological classification of CMN 55 
includes three subtypes, i.e. the classic, cellular and mixed type [10-12]. Recurrent genetic 56 
aberrations described in CMN include somatic trisomy 11 and t(12;15)(p13;q25), resulting in a 57 
fusion of ETV6 and NTRK3 [13,14].  58 
The vast majority of CMN patients seems to present with local disease. Complete nephrectomy 59 
is considered the standard of care for children with CMN, although use of adjuvant 60 
chemotherapy and even radiotherapy has been reported [2,15,16]. These treatment strategies are 61 
mainly based on the few published CMN series with substantial numbers. A significant number 62 
of CMN patients have been described in case reports and to date a comprehensive review is not 63 
available. The aim of this narrative review was to gain insight into the clinical characteristics, 64 
histological subtypes, genetic aberrations, treatment modalities and outcome of patients with 65 
CMN, in order to develop future treatment strategies. 66 
 67 
Methods 68 
For this review, databases of PubMed, Embase, Web of Science, Scopus and Google scholar 69 
were searched using search terms “mesoblastic nephroma”, “mesoblast” within 3 words of 70 
“nephrom”, “non-Wilms” or “not-Wilms” (mesoblastic nephroma*[tw] OR (mesoblast*[tw] 71 
NEAR/3 nephrom*[tw])) OR non-Wilms*[tw] OR not-Wilms*[tw]). After removal of double 72 
articles, 984 articles published before 1 December 2015 remained (Fig 1). Thirteen articles were 73 
added after hand searching. Articles were selected on the basis of title and abstract by two 74 
independent reviewers (S.L.G. and T.D.) (Fig 1). To be eligible for inclusion, a study had to (1) 75 
contain well-described CMN patients <18 years of age, (2) be an original article, (3) be reported 76 
after the study by Bolande et al (1967), (4) be written in English language and (5) be available in 77 
full-text. In case of doubt about the histological diagnosis or in case the tumor was described 78 
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under a different name, the paper was reviewed extensively by an expert pathologist (G.J.V.) 79 
before inclusion in the current review. 80 
 81 
Results 82 
A total of 200 articles met the inclusion criteria (Fig. 1). Of these, 25 articles reported series of 83 
≥10 patients which included 628 patients in total (Table 1, Supplemental Table S1). Where more 84 
than one paper reported on the same or overlapping cohorts, the report with the most detailed 85 
information on the largest number of individuals was used; eventually 12 non-overlapping series 86 
including 306 patients were selected for the analysis in this review (Table 1). 87 
In addition to these series, 174 case reports described 270 cases in total (Supplemental Table S2). 88 
Data of these case reports were only included in the analysis of this review if they provided well 89 
documented data and relevant additional information, such as the correlation between genotype 90 
and histology and characteristics of stage III or relapsed CMN patients. 91 
 92 
Clinical characteristics 93 
Median age at diagnosis ranged from 0 days (newborn) - 2.3 months (median age ≤1 month in 94 
63% of series) and overall age ranged from prenatal - 3.8 years (Table 1). Prenatal detection of 95 
the tumor was reported in 16% of the patients [15,17-19]. The male to female ratio was 1.5:1 96 
(Table 1). The most commonly reported presenting symptom was an abdominal mass, described 97 
in 76% of the cases (Table 1). Other repeatedly reported symptoms were hypertension (19%) and 98 
hematuria (11%) (Table 1). Case reports additionally reported polyhydramnios in 40/270 cases 99 
(15%), hypercalcemia in 12/270 cases (4%) and hyperreninemia in 3/270 cases (1%) 100 
(Supplemental Table S2). Both hypercalcemia and hyperreninemia completely resolved with 101 
removal of the tumor in all cases [5,20-34].  102 
Congenital anomalies were reported in 11 patients described in series; genitourinary anomalies 103 
were described in 6 patients, gastrointestinal malformations in 2 patients, polydactyly in 1 104 
patient, hydrocephalus in 1 patient and 1 patient was described to be diagnosed with the 105 
Beckwith-Wiedemann syndrome (BWS) [2,15,18,35]. In case reports, 2 additional patients with 106 
BWS were diagnosed with CMN [5,36]. 107 
 108 
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CMN is classified into three histological subtypes: classic, cellular and mixed type. Classical 110 
type CMN shows a leiomyomatous pattern resembling infantile fibromatosis composed of 111 
interlacing bundles of spindle cells and low mitotic activity, no capsule, infiltrative growth into 112 
the renal parenchyma and/or perirenal fat, and entrapped islands of parenchyma [37]. The 113 
cellular type, identical to infantile fibrosarcoma, shows dense cellularity, a strong 114 
hemangiopericytous vascular pattern and a high mitotic activity but less infiltrative growth into 115 
the renal parenchyma [10,37]. Mixed type CMN shows a mixture of these two patterns in any 116 
proportion [37]. Information on histological subtype was available for 231 patients; the classic 117 
type occurred in 91 patients (39%), the cellular type in 96 patients (42%), the mixed type in 23 118 
patients (10%) and classic/mixed type (no discrimination) in 21 patients (9%) (Table 1). In three 119 
series a significant difference in age between classic (median age ranging between 6-17 days) 120 
and cellular type CMN (median age ranging between 3.7-5 months) was reported [15,16,19]. The 121 
median age of mixed type CMN was described in only one series, i.e. 1.9 months [16].  122 
Information on stage was available for 251 patients; stage I/II disease was found in 208 patients 123 
(83%) and stage III disease in 42 patients (17%) (Table 1). Reasons for stage III disease were 124 
positive surgical margins (n=13), tumor rupture (n=12) or a combination of positive surgical 125 
margins and tumor rupture (n=11), while in 8 patients the reason for stage III was unknown 126 
[2,10,15-18,38-40]. One patient was described to have stage IV disease because of ‘suspected’ 127 
malignant cells in the bone marrow, however these cells were not histologically proven to be 128 
CMN cells, so we consider this case not being stage IV [35]. In case reports, another case was 129 
described to have stage IV disease at diagnosis (lesions in the right tibia on CT scan, however no 130 
histological confirmation available) [41]. Bilateral (stage V) disease has never been reported. 131 
Stage in relation to histological type is presented in Figure 2. 132 
Data on immunohistochemistry were described in one series, showing immunoreactive renin 133 
(intense staining in vessels within areas of the trapped cortex) in 10/12 studied cases [38,39]. 134 
Case reports provided information on immunohistochemical staining in 53 cases. In these cases, 135 
in total 27 different immunohistochemical markers were used. No marker specific for CMN 136 
could be identified (Supplemental Table S3). 137 
 138 
Genetics 139 
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The most commonly reported genetic aberrations in CMN are t(12;15)(p13;q25), leading to a 140 
fusion of the genes ETV6 and NTRK3, and trisomy 11 (both somatic). In Table 2, information on 141 
stage, histological type and outcome is provided for cases harboring t(12;15)(p13;q25) and cases 142 
harboring trisomy 11. In series, t(12;15)(p13;q25) and trisomy 11 were identified in 29% and 143 
54% of the analyzed cases, respectively [13,18,19,40]. No clear relation between stage and 144 
genetic subtype could be identified. Both genetic aberrations occurred in mixed/cellular type 145 
CMN only, and never in the classic type of CMN (Table 2). Median ages of patients harboring 146 
t(12;15)(p13;q25) and patients harboring trisomy 11 were both 1 month. 147 
Other recurrently reported genetic aberrations in CMN (in case reports) are trisomies 8 (n=9), 17 148 
(n=4), 20 (n=4), 7 (n=3), 10 (n=3), 18 (n=2), 2 (n=2) and 9 (n=2) (Supplemental Table S2); all 149 
identified aberrations only occurred in mixed/cellular type CMN. 150 
 151 
Treatment 152 
Treatment details were available for 263 patients. Pre-operative chemotherapy was administered 153 
in only 9 patients, consisting of actinomycin and vincristine (AV) in 8 patients and unknown 154 
type of treatment in one patient [15,16,18]. Information on response to pre-operative 155 
chemotherapy was described in 6 cases; 5 cases treated with AV showed a reduction in tumor 156 
size of at least 30% and one case treated with AV had a significant increase in tumor size, but 157 
histology at time of surgery showed 80% necrosis [15,16].  158 
All patients underwent surgery (179 complete nephrectomy, 6 partial nephrectomy (re-excision 159 
n=3), 77 unknown type of surgery), except for one patient who died before surgery could be 160 
applied.  161 
Post-operative chemotherapy had been administered in 50 patients, consisting of AV in 21 cases, 162 
actinomycin alone in 11 cases, AV and doxorubicin in 3 cases, AV and cyclophosphamide in 1 163 
case, etoposide/cyclophosphamide/doxorubicin/carboplatin in one case and in 13 cases type of 164 
post-operative chemotherapy was unknown [2,10,15,16,18,35,38,39,42]. Radiotherapy was 165 
applied in nine cases [2,10,15,35]. 166 
 167 
Outcome 168 
Information on outcome was available for 276 patients described in series (Table 1). Of these, 169 
264 patients survived (96%) and 12 patients died (4%). Causes of death in these 12 patients were 170 
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disease-related in 5 cases and treatment-related in 7 cases (5 surgery-related, 2 chemotherapy-171 
related) (Supplemental Table S4). Median age at diagnosis of patients who died of disease was 6 172 
months, while median age at diagnosis of patients who died of treatment-related causes was 0 173 
days (newborn). Surgery-related causes of death included post-operative sepsis (n=2), post-174 
operative necrotizing enterocolitis (n=1), intra-operative bleeding (n=1) and ‘not specified’ 175 
(n=1).  Chemotherapy-related causes of death consisted of severe neutropenia and sepsis (n=2). 176 
Information on occurrence of relapse was available for all 306 patients described in series. 177 
Relapses occurred in 12 patients (4%) (9 local, 2 metastatic in lung and bone, 1 location 178 
unknown) (Supplemental Table S5). The histological subtype was known in 11 relapsed cases (8 179 
cellular, 1 classic, 2 mixed). Information on outcome after relapse was available in 10 cases; 6 180 
achieved a second complete remission and 4 patients died of disease (Supplemental Table S5).  181 
 182 
Prognostic value of stage, histologic subtype and genetic aberrations 183 
Information on outcome according to stage was available for 145 patients described in series. Of 184 
125 patients with stage I/II disease, 4 patients (3%) suffered from a relapse and 6 patients (5%) 185 
died (3 of treatment-related toxicity and 3 of disease) (Supplemental Table S4 and S5). Of note, 186 
only 1 of 100 (1%) stage I/II patients treated with surgery alone, developed a relapse. Of 34 187 
patients with stage III disease, 6 patients (18%) had a relapse (4 cellular, 1 mixed, 1 unknown 188 
histology) and 2 patients (11%) died of tumor progression (both cellular) (Supplemental Table 189 
S4 and S5). As this is only a small set of patients, we also analyzed stage III patients as described 190 
in case reports. Stage III patients reported in case reports (n=22), together with stage III patients 191 
reported in series (n=34) are described in Supplemental Table S6; 15/56 stage III patients (23%) 192 
suffered from a relapse (73% cellular subtype) and 4/56 patients (6%) died of disease (all cellular 193 
subtype). 194 
Information on outcome according to histological subtype was available for 156 patients 195 
described in series. Of 74 patients with classic type CMN, 1 patient (1%) (stage II) had a relapse 196 
and another patient (1%) (stage II) died of surgical complications (Supplemental Table S4 and 197 
S5). Of 59 patients with cellular type CMN, 6 patients (10%) (1 stage I, 1 stage II, 4 stage III) 198 
had a relapse and 4 patients (7%) (1 stage I, 1 stage II and 2 stage III) died of disease 199 
(Supplemental Table S4 and S5). Of 23 patients with mixed type CMN, one patient (4%) (stage 200 
III) had a relapse, but was alive after treatment (Supplemental Table S5 and S6). 201 
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Outcomes of patients harboring t(12;15)(p13;q25) and trisomy 11 are described in Table 2. 202 
 203 
Discussion 204 
The aim of this narrative review was to present a comprehensive and up-to-date overview of 205 
clinical characteristics, optimal treatment strategies and outcome of different histological and 206 
genetic subtypes of CMN, thereby serving future treatment guideline development for this rare 207 
tumor.  208 
Most studies reporting on CMN have not been based on (inter-)national registries. Therefore, the 209 
prevalence of CMN and its histological subtypes is hard to analyze. Large series have suggested 210 
that CMN comprises 3.5-4% of all pediatric renal tumors, but it is conceivable that perinatal 211 
diagnosed cases may have been considered benign, and therefore not have been included in renal 212 
tumor registries [15,16]. The frequency of the cellular subtype and classic subtype seems to be 213 
similar, while the mixed subtype occurs remarkably less often (±10%) [15,16,19].  214 
CMN most commonly occurs early in infancy and over 15% of the cases are detected prenatally 215 
[13,15,16,35,38,39]. Although CMN has been reported in 26 adult patients in literature, it 216 
remains uncertain whether these cases are real CMN’s [43-62]. It is believed that most of these 217 
so-called adult mesoblastic nephromas are now recognized to have represented other tumors, 218 
such as metanephric stromal tumor, cystic hamartoma of the renal pelvis or mixed epithelial and 219 
stromal tumor [63,64]. For this reason, adult cases have been excluded from the current review. 220 
Two major genetic variants have recurrently been described in CMN; t(12;15)(q13;q25), 221 
resulting in a fusion of ETV6 and NTRK3, and trisomy 11 [13,18,19,40]. These genetic 222 
aberrations were only identified in cellular and (less common) mixed type CMN. Of interest, the 223 
other recurrently but rarely reported genetic aberrations (i.e. trisomy 2/8/9/10/17/18/20) also only 224 
occurred in mixed and cellular type CMN [30,65-72]. This clonality may be illustrative for more 225 
malignant disease as these are the subtypes that seem to behave more aggressively. However, no 226 
biological studies have been performed to functionally verify this, as yet. We assume that all 227 
aforementioned genetic aberrations are somatic, since no germline genetic aberrations associated 228 
with CMN have been described. This is in line with the observation that bilateral CMN has never 229 
been reported. Besides the diagnosis of Beckwith-Wiedemann syndrome in 3 CMN patients, no 230 
association with genetic predisposition syndromes has been reported up until now [5,18,36]. 231 
Occurrence of CMN in two siblings has been reported once [73].  232 
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Overall survival of CMN patients was excellent (5-year overall survival ±95%). Nevertheless, it 233 
was not 100% as suggested in earlier reports [16,42]. It is remarkable that causes of death were 234 
treatment-related in about half of the cases and most of these patients were very young (median 235 
age at diagnosis: 0 days, newborn) [2,10,13,15,17,18,35,38,39]. This underscores that these 236 
infants with renal tumors deserve special attention with respect to timing and type of treatment, 237 
and need a dedicated expert pediatric oncology setting. Relapses were described in only 4% of 238 
the patients [2,13,15,18,19,35]. Virtually all relapses occurred within 12 months after diagnosis, 239 
indicating that close monitoring of all cases should be advised for at least 1 year following end of 240 
treatment. Most relapses occurred locally, however also metastatic relapses have been reported 241 
(Supplemental Table S5). About 69% of the relapsed patients survived after relapse treatment 242 
consisting of individualized combinations of surgery, chemotherapy and radiotherapy 243 
(Supplemental Table S5) [2,13,15,18,19,35]. 244 
Factors that seem to negatively influence outcome of CMN patients were stage III disease and 245 
cellular subtype (Supplemental Table S4, S5 and S6) [15]. In addition to these factors, 246 
Furtwangler et al. described age ≥ 3 months to be associated with the occurrence of relapse based 247 
on a univariate analysis of 50 CMN cases, which can probably be attributed to the observation 248 
that the more aggressive cellular subtype occurs most often in older patients [15]. According to 249 
the current review, patients with relapse indeed seemed to be slightly older (median age 250 
approximately 3.8 months) compared to patients without relapse (median age <1 month) 251 
(Supplemental Table S5). In contrast, most deceased CMN patients were relatively young 252 
(median age 0 days, newborn), mainly due to the high incidence of treatment-related mortality 253 
among these very young patients (Supplemental Table S4). It is currently not possible to 254 
elucidate the prognostic value of t(12;15)(p13;q25) and trisomy 11 in CMN patients due to lack 255 
of published data [13,18,19]. 256 
Designing a standard of care for CMN patients is a challenge based on the limited available 257 
evidence. It is obvious that patients with stage I/II disease, representing over 80% of the CMN 258 
patients, benefit from a surgery only strategy [15,16,74]. Particularly in CMN cases, removing 259 
perirenal fat during surgery is considered the golden standard, as CMN tumors often show 260 
infiltrative growth into the perirenal fat [1]. Throughout the world immediate surgery is 261 
recommended for renal tumors in patients under 6 months of age due to the higher probability of 262 
pathology other than Wilms’ tumor in this age group [4,75]. However, consideration of pre-263 
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operative chemotherapy (AV) may be justified in a small subset of these young patients, when 264 
imaging or clinical symptoms suggest a high risk of operative or anesthetic complications or 265 
inoperability, even by an experienced surgical team. Partial nephrectomy or nephron-sparing 266 
surgery has only been performed in a small subset of patients and in 3 of 6 such cases, re-267 
excision was necessary [15]. It is important that, especially in the neonatal setting, the risk of 268 
surgery should be weighed carefully against the risk of pre-operative chemotherapy. 269 
Stage III CMN patients represent a challenging subgroup with respect to the development of 270 
proper guidelines. For most of the cases surgery only seems to be sufficient, especially for stage 271 
III cases of the classic or mixed histological subtype. Of 12 well-documented classic and mixed 272 
type stage III patients treated without additional chemotherapy, one patient (8%) suffered from a 273 
relapse, but survived after relapse treatment (Supplemental Table S6). In contrast, 7/12 (58%) 274 
stage III cases of the cellular type treated with surgery only suffered from a relapse, while 4/14 275 
(29%) stage III cellular type cases treated with adjuvant chemotherapy developed a relapse. 276 
Hence, evidence that additional chemotherapy is reasonable for stage III cellular type cases is not 277 
available due to a small dataset including selected subjects (Supplemental Table S6) [15,16,18]. 278 
Chemosensitivity is documented in CMN patients; treatment of patients with pre-operative 279 
actinomycin/vincristine resulted in a reduction in tumor size or necrotizing of the tumor in all 280 
reported patients [15,16]. In addition, Loeb et al described three patients with recurrent cellular 281 
CMN who showed a complete response to different combinations of chemotherapy 282 
(Supplemental Table S5) [76]. However, based on the results of this review, caution with respect 283 
to chemotherapy-related toxicity is important in these young children (Supplemental Table S4). 284 
Targeted therapy might be an option for cases with progressive disease that do not respond to 285 
chemotherapy. In particular Crizotinib, an ALK inhibitor which proved to be of benefit for acute 286 
lymphoblastic leukemia patients harboring the ETV6-NTRK3 transcript, resulting from the same 287 
t(12;15)(p13;q25) as described in CMN cases, could be considered as a potential compound in 288 
highly selected aggressive cases [77]. The role of radiotherapy for CMN patients is uncertain, 289 
and considering the fact that late effects of radiotherapy are suspected to be substantial in this 290 
relatively young group of patients, radiotherapy should be reserved for highly selected, 291 
aggressive and chemotherapy resistant cases only. 292 
Because of the small number of relapsed CMN patients and the different treatment regimens 293 
applied in these patients, designing evidence-based treatment guidelines for relapsed CMN is not 294 
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possible. Treatment of such patients requires an individualized approach in dedicated centers for 295 
pediatric oncology. 296 
Based on this overview, we conclude that CMN is a disease that presents at young age, most 297 
commonly in the first months of life. Most CMN patients present with stage I/II disease, for 298 
which surgery only is the recommended treatment. Based on the very limited available data, 299 
partial nephrectomy or nephron-sparing surgery is currently not recommended for CMN patients. 300 
There is insufficient evidence for recommending adjuvant chemotherapy in patients with stage 301 
III disease, due to the small number of reported cases and lack of clinical trials. Histologically 302 
confirmed stage IV or stage V CMN cases have not been described. Although initial surgery is 303 
recommended for renal tumors in patients under 6 months of age, consideration of pre-operative 304 
chemotherapy may be justified in a small subset of young patients, when imaging or clinical 305 
symptoms suggest a high risk of operative of anesthetic complications. Survival rates of reported 306 
CMN patients were excellent (approximately 95% overall survival). Factors that seemed to be 307 
associated with occurrence of relapse were stage III disease and cellular histology. The 308 
prognostic value of t(12;15)(p13;q25) and trisomy 11, only described in cellular and mixed type 309 
CMN, is hard to elucidate based on the small number of series with available data. Despite the 310 
excellent outcome of patients diagnosed with CMN, the risk of treatment-related complications 311 
(both surgery and chemotherapy related complications) seems to be relatively high, especially 312 
when the tumor appears in the first weeks of life. This indicates that these very young patients 313 
deserve special attention with respect to the timing and type of treatment, that they need a 314 
dedicated expert pediatric oncology setting, and that close monitoring of toxicity is needed. It is 315 
recommended to discuss rare challenging individual CMN cases (such as (cellular) stage III and 316 
relapsed cases) with steering committees of pediatric renal tumor boards, such as SIOP 317 
(International Society of Pediatric Oncology) and COG (Children’s Oncology Group). The 318 
results of this review have guided the design of new CMN treatment recommendations, which 319 
will be included in the international SIOP RTSG 2016 UMBRELLA protocol, however they 320 
illustrate that longitudinal prospective registries that include histology as well as molecular 321 
diagnostics are necessary for further evidence-based treatment and guideline development for 322 
patients with CMN. 323 
 324 
 325 
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Author, year M/F L/R 
Median age 
(range) 







AM HT HE Other I/II III IV Pr-CT S P-CT RT Cl M Ce t(12;15) Trisomy 11 
1. Howell, 1982 33/18 26/25 2.3m 48 2 9 6 39 12 0 - 51 28 4 NA NA NA 98% 98%  3.2y (4m-11.5y) 
2. Sandstedt, 1985 11/18 13/16 NA 18 - 5 5 21 8 0 - 29 5 1 9 - 20 NA NA 93% 93%  > 4y 
3. Cook, 1988 / 
Malone, 1989 ¶ 
9/3 3/9 3d (1d-2.5y) 11 4 1 NA* 11 1 0 - 12 1 - NA NA NA 83% 83%  7.3y † 
4. Barrantes, 1991 8/5 9/4 0d  (0d-19m) NA* - - - 12 0 1 # - 13 4 3 9 1 3 NA NA 85% 85%  5.8y 
5. Leclair, 2005 NA NA NA NA 25 1 0 - 26 - - 21 5 NA NA 96% 96%  ±3.5y 
6. Anderson, 2006 NA NA 2m (0d-11m) NA 11 2 0 - 13 - - 3 6 4 3/13 NA 85% 100% NA 
7. Furtwaengler, 2006 34/16 21/29 18.5d (0d-2.6y) 27 16 1 6 41 9 0 5 50 6 1 29 - 21 NA NA 94% 95%  4.2y (0.8-8.3y) 
8. Watanabe, 2007 7/6 NA 30d (5d-7m) NA NA NA 4 1 8 8/12 7/13 92% 92%  NA 
9. Bayindir, 2009 7/3 5/5 3.1m (6d-5.5m) 9 7 2 4 7 3 0 2 9 2 - 2 2 6 2/10 NA 70% 90%  3.6y (6m-7y) † 
10. Chaudry, 2009 15/15 14/16 NA NA* - - - NA NA 30 NA NA 12 3 15 6/30 NA 93% NA NA 
11. England,  2011 28/19 23/24 1m (0d-3.8y) NA* NA* - - 41 6 0 2 47 2 - 23 10 14 NA NA 100% 100%  4.4y (1m-10y) 
12. Saula, 2012 7/5 NA NA  12 2 - 2 NA - 12 2 - NA NA NA 92% 100%  5-10y 
Total  159/108 114/128 Range 0d-2.3m 125 31 18 23 208 42 1 9 292 50 9 91 23 96 16/52 7/13 94% 95% Range 3.5-5.8y 
Abbreviations AM: abdominal mass, BM: bone marrow, Ce: cellular type, Cl: classic type, d:days, EFS: event free survival, F: female, HC: hypercalciaemia, HE: hematuria, HT: hypertension, L: left, M: male, M: mixed type, m: 
months, NA: not available, NB: newborn, OS: overall survival, PH: polyhydramnion mother, P-CT: post-operative chemotherapy, Pr-CT: pre-operative chemotherapy, R: right, RT: radiotherapy, S: surgery, y: years 
¶ Cook et al (1988) and Malone et al (1989) described the same series of CMN patients with different endpoints 
#  Suspected malignant cells in bone marrow, no histological confirmation of CMN 
* Symptom reported, number of patients unknown  
† Mean follow-up instead of median follow-up 
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Table 2. Stage, histology and outcome of reported CMN cases harboring t(12;15)(p13;q22) or trisomy 11  
 
 t(12;15)(p13;q22) * Trisomy 11 * 
Series ≥ 10 patients  Case reports ** Series ≥ 10 patients Case reports ** 
Number of cases 
analyzed 
65 NA 13 NA 
Number of positive cases 19 16 7 15 




























Outcome data available n = 13 n = 5 n = 7 n = 4 
Outcome Relapse: 2/13 
Dead of disease: 1/13 
Relapse: 2/5 
Dead of disease: 0/5 
Relapse: 0/7 
Dead of disease: 0/7 
Relapse: 0/4 
Dead of disease: 0/4 
* Six cases described in series ≥ 10 patients and 11 cases described in case reports harbored both t(12;15)(p13;q22) and trisomy 11 
** Case reports also included in series ≥ 10 patients were removed from this table 
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Supplemental Table S1. Available series reporting ≥ 10 CMN patients 
 
 
Author, year M/F L/R 
Median age 
(range) 







AM HT HE Other I/II III IV Pr-CT S P-CT RT Cl M Ce t(12;15) Trisomy 11 
NON-OVERLAPPING SERIES 
1. Howell, 1982 33/18 26/25 2.3m 48 2 9 6 39 12 0 - 51 28 4 NA NA NA 98% 98%  3.2y (4m-11.5y) 
2. Sandstedt, 1985 11/18 13/16 NA 18 - 5 5 21 8 0 - 29 5 1 9 - 20 NA NA 93% 93%  > 4y 
3. Cook, 1988 / 
Malone, 1989 ¶ 
9/3 3/9 3d (1d-2.5y) 11 4 1 NA* 11 1 0 - 12 1 - NA NA NA 83% 83%  7.3y † 
4. Barrantes, 1991 8/5 9/4 0d  (0d-19m) NA* - - - 12 0 1 # - 13 4 3 9 1 3 NA NA 85% 85%  5.8y 
5. Leclair, 2005 NA NA NA NA 25 1 0 - 26 - - 21 5 NA NA 96% 96%  ±3.5y 
6. Anderson, 2006 NA NA 2m (0d-11m) NA 11 2 0 - 13 - - 3 6 4 3/13 NA 85% 100% NA 
7. Furtwaengler, 2006 34/16 21/29 18.5d (0d-2.6y) 27 16 1 6 41 9 0 5 50 6 1 29 - 21 NA NA 94% 95%  4.2y (0.8-8.3y) 
8. Watanabe, 2007 7/6 NA 30d (5d-7m) NA NA NA 4 1 8 8/12 7/13 92% 92%  NA 
9. Bayindir, 2009 7/3 5/5 3.1m (6d-5.5m) 9 7 2 4 7 3 0 2 9 2 - 2 2 6 2/10 NA 70% 90%  3.6y (6m-7y) † 
10. Chaudry, 2009 15/15 14/16 NA NA* - - - NA NA 30 NA NA 12 3 15 6/30 NA 93% NA NA 
11. England,  2011 28/19 23/24 1m (0d-3.8y) NA* NA* - - 41 6 0 2 47 2 - 23 10 14 NA NA 100% 100%  4.4y (1m-10y) 
12. Saula, 2012 7/5 NA NA  12 2 - 2 NA - 12 2 - NA NA NA 92% 100%  5-10y 
Total  159/108 114/128 Range 0d-2.3m 125 31 18 23 208 42 1 9 292 50 9 91 23 96 16/52 7/13 94% 95% Range 3.5-5.8y 
PARTIALLY OVERLAPPING SERIES 
Bogdan, 1973 ^1 14/5 NA 4w (0d-2.5y) 15 - - 4 NA 2 15 5 8 NA NA NA 68% 68% 1.8y (0m-34y) 
Shen, 1980 ^1 5/5 7/3 5d (1d-8m) 10 1 2 1 NA - 10 4 - 5 3 2 NA NA 90% 90% 4.5y (3.3-10y) 
Snyder 1980 ^1 8/3 NA 0d(0d-6m) NA*   3 11 0 0 - 11 - 5 9 - 2 NA NA 73% 73% NA (3-26y) 
Hartman, 1981 ^1 9/11 NA 2w (0d-16y) NA NA NA NA NA NA NA NA NA 
Chan, 1987 ^1 9/8 NA 
Cl:5.3d (1-21d) 
Ce:5.3m (1-18m) 
NA* 14 3 6 17 0 0 - 17 3 2 9 8 NA NA 100% 100% 10y † 




NA* 2 2 3 15 1 0 0 14 1 - 6 3 7 NA NA 81% 81% 5.3y † 
Schofield, 1993 ^1 8/9 NA 7d (1d-2y) NA NA 0 17 5 - 6 5 5 NA 7/17 88% 88% Range 8m-22y 
Mascarello, 1994 ^1,10 NA NA NA NA NA NA 11 12 NA 9/23 NA NA NA 
O'Malley, 1996 ^1 9/6 NA NA(2d-2y) NA NA - 15 1 - 1 6 9 NA NA NA NA NA 
Knezevich, 1998 ^9,10 8/7 NA 1m (1d-3y) NA NA NA 4 2 9 10/15 9/14 NA NA NA 
Shao, 2004 ^1,9,10 NA NA NA NA NA NA 5 - 7 NA NA NA NA NA 
Abosoudah, 2008 ^10 8/6 NA 12d (3d-2y) NA* - - - NA NA 4 1 9 9/10 NA 86% 93% NA 
Vd Heuvel-Eibrink, 
2008 ^7 
NA NA < 7m NA 98 17 0 NA NA NA NA 94% 96% NA 
Abbreviations   AM: abdominal mass,  BM: bone marrow, Ce: cellular type,  Cl: classic type, d:days, EFS: event free survival, F: female, HC: hypercalciaemia, HE: hematuria, HT: hypertension, L:left, M: male, M: mixed type, m: 
months, NA: not available, NB: newborn, OS: overall survival, PH: polyhydramnion mother, P-CT: post-operative chemotherapy, Pr-CT: pre-operative chemotherapy, R: right, RT: radiotherapy, S: surgery, y: years 
^ Overlap of patients with other series (number of overlapping series is depicted, for example ^1 means overlap with the study by 1. Howell, 1982) 
¶ Cook et al (1988) and Malone et al (1989) described the same series of CMN patients with different endpoints 
#  Suspected malignant cells in bone marrow, no histological confirmation of CMN 
* Symptom reported, number of patients unknown  
† Mean follow-up instead of median follow-up 
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Supplemental Table S2. CMN patients described in case reports
Study (year) Sex Age at 
diagnosis 



















Adem -1 (2001) M NA NA NA NA NA NA NA Cellular NA
t(12;15)(p13;q25), 
trisomy 11 NA NA NA NA
Adem -2 (2001) NA NA NA NA NA NA NA NA Classic NA NA NA NA NA NA
Al-Turkistani 
(2008) F PN: GA 26 w R
Fetal abdominal mass*, 
polyhydramnios* No NA
Total nephrectomy 4 
weeks after birth NA Mixed 4x5x4,5cm NA NA NA NA NA
Ali (1994) M PN: GA NA L Fetal abdominal mass* NA NA
Total nephrectomy 3 
days after birth NA Cellular NA NA Relapse Died 9 Tumor progression
Angulo (1991) M 14 D R
Congenital hypertrophic 
pyloric stenosis, renal tumor 
found during pyloromyotomy NA No Total nephrectomy I Cellular NA NA No relapse Alive 108 .
Angulo  (1991) M PN: GA 37 w R Stillborn No NA No surgery (stillborn) NA Classic NA NA Stillborn Died 0
Stillborn (hydrops 
fetalis)
Anunobi (2014) F 0 D (NB) L
Stillborn, abdominal mass, 
polyhydramnios* NA NA No surgery NA Classic 5x5x3cm NA Died Died 1 day
Patient died due 
to complications 
of prematurity, 
tumor found at 
Arensman (1980) M 4 D L Left flank mass No Yes Total nephrectomy III NA NA NA No relapse Alive 24 .
Argani -1 (2000) M 14 Mo NA NA NA NA
Tumor resection (total 
nephrectomy?) II Cellular NA t(12;15)(p13;q25) Relapse Alive 84 .
Argani -2 (2000) M 11 Mo NA NA NA NA Total nephrectomy NA Cellular 980 gram t(12;15)(p13;q25) NA NA NA NA
Bandyopadhyay -1 
(2009) F 3 Mo NA Abdominal mass NA NA Total nephrectomy I Classic 8,5x5x4cm NA No relapse Alive 24 .
Bandyopadhyay -2 
(2009) M 2.5 Mo NA Abdominal mass NA NA Total nephrectomy I Classic 9x6x4cm NA No relapse Alive 24 .
Bandyopadhyay -3 
(2009) F 3 Mo L Abdominal mass, vomiting NA NA Total nephrectomy I Cellular 8x5x4cm NA No relapse Alive 24 .
Bauer (1979) F 3 Mo R
Abdominal distention, 
vomiting, diarrhea, 
hyperreninemia NA NA Total nephrectomy II NA
9.5cm 
(diameter) NA No relapse Alive 18 .
Becroft (1995) F 1 Mo L Abdominal mass No NA
Tumor resection (total 





biallelic expression No relapse Alive 48 .
Bell (2002) F 9 Mo R
Low-grade fever, abdominal 
distension, diarrhoea, 
general malaise No NA
Partial resection 
(infiltration 
duodenum and colon) III Mixed 16x6x7cm NA Relapse NA NA NA
Bendre -1 (2014) M 2 Mo R Abdominal mass NA No Total nephrectomy NA Classic 9.3x3x3cm NA No relapse Alive 22 .
Bendre -2 (2014) M 3 Mo R
Abdominal mass, 
hypertension NA No Total nephrectomy NA Classic NA NA No relapse Alive 24 .
Bernstein (1994) F 5 w L
Abdominal distention, crying, 
decreased appetite No NA
Nephrectomy (95% of 





add(12)(p130) NA NA NA NA
Bisceglia (2000) F 0 D (NB) R Abdominal mass No NA
Total nephrectomy 1 










content No relapse Alive 72 .
Blank -1 (1978) M 0 D (NB) R
Abdominal mass, 
polyhydramnios*, premature 
delivery at 32 weeks 
gestation No NA
Total nephrectomy 4 
days after birth NA NA NA NA No relapse Alive 6 .




(timing unknown) NA NA NA NA Died Died 0
Fatal tear in 
inferior vena cava 
during 
nephrectomy
Blank -3 (1978) F 0 D (NB) R
Abdominal mass, 
polyhydramnios* NA NA
Total nephrectomy 8 
days after birth NA NA NA NA No relapse Alive 12 .
Bolande -1 (1967) M 0 D (NB) R
Abdominal mass, transient 
hyperbilirubinaemia NA NA
Total nephrectomy 1 
week after birth NA NA NA NA No relapse Alive 72 .
Bolande -2 (1967) F 0 D (NB) L Abdominal mass NA NA
Total nephrectomy 5 
days after birth NA NA NA NA No relapse Alive 12 .
Bolande -3 (1967) F 0 D (NB) NA
Abdominal mass, respiratory 
distress, sepsis, 
hyperbilirubinaemia NA NA
Total nephrectomy 3 
weeks after birth NA NA NA NA No relapse Alive 72 .
Bolande -4 (1967) M 3 Mo R Abdominal mass NA NA Total nephrectomy NA NA NA NA No relapse Alive 72 .
Bolande -5 (1967) F 0 D (NB) R Abdominal mass NA NA
Total nephrectomy 2 
days after birth NA NA NA NA Died Died 0.4
Pseudomonas 
sepsis on 12th 
post-operative day
Bolande -6 (1967) F 0 D (NB) L Abdominal mass NA NA
Total nephrectomy in 
first week after birth NA NA NA NA No relapse Alive 60 .
Bolande -7 (1967) M 0 D (NB) R Abdominal mass NA NA
Total nephrectomy in 
first week after birth NA NA NA NA No relapse Alive 36 .
Bolande -8 (1967) F 0 D (NB) L Abdominal mass NA NA
Total nephrectomy 2 
months after birth NA NA NA NA No relapse Alive 180 .
Campagnola 
(1998) M 4 Mo L Abdominal distention NA NA Total nephrectomy NA Cellular 17x17cm NA No relapse Alive 48 .
Campos (2001) NA 0 D (NB) R Abdominal mass NA NA
Total nephrectomy 6 
days after birth I Cellular NA NA No relapse Alive 24 .
Carpenter (1993) F PN: GA 36 w L Fetal abdominal mass* NA NA
Total nephrectomy 
(timing unknown) I Mixed 8x5x4,5cm
46X-X, 
t(12;15)(p13;q25), 
trisomy 11 No relapse Alive 19 .
Celik (2009) M PN: GA 28 w L
Fetal abdominal mass*, 
polyhydramnios* NA No
Total nephrectomy 3 
days after birth NA Cellular
6x5,5x4,5c
m NA NA NA NA NA
Chan (1995) F 3 D R Abdominal mass, vomiting NA No Total nephrectomy III Cellular
6.5cm 
diameter NA No relapse Alive 12 .
Chan -1 (2002) NA PN: GA 30 w NA Fetal abdominal mass* NA No
Total nephrectomy 
after 1 course of 
vincristine NA NA NA NA No relapse Alive 84 .
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Supplemental Table S3. Immunohistochemical staining of 53 CMN patients described in case reports 
Staining Positive Negative 
Classic Mixed Cellular NA Classic Mixed Cellular NA 
Vimentin 7 5 17 3 1 2   
Desmin    3 3 2 9 2 
(Smooth muscle) actin 3 3 5 3 2 1 5  
(Cyto)keratin 1  2  3 1 7  
S-100  1   2 1 3  
Neuronspecific enolase     1  1  
TrkC antibody   1      
Epithelial membrane 
antigen 
3 3 3  2  7  
AE1/AE3 2 2 2  1 1 1  
PTHrP  1 1      
c-kit    2 1    
Ki-67 1  4  1    
CD34 1    2  4  
Myoglobin       1  
Alpha-fetoprotein       1  
Bcl-2       1  
CD99       1  
INI1   4      
Fibronectin 1 1 2      
Laminin     1 1 2  
TP     2 3 2  
PHA     3 2 2  
THP 1  1  1 2 1  
AH 3 3 2      
PSA 1 1 1  2 2 1  
WT1-GP   1 1     
Renin        1 
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Supplemental Table S4. Characteristics and treatment of reported deceased CMN patients 
Type of report Report Age Stage Histologic 
subtype 
Tx at diagnosis Relapse Cause of death 
Series ≥ 10 
patients 
 
Furtwangler 2006 6m III Cellular PN, CN (rupture) Yes  Tumor progression 
Furtwangler 2006 2.7y I Cellular Pre-op CT, CN, 
post-op CT 
Yes Tumor progression 
Bayindir 2009 3.9m III Cellular Pre-op CT No Tumor progression 
Watanabe 2007 1.1y II Cellular CN, post-op CT 
(NWTS-3 
regimen K) 
Yes Tumor progression 
Leclair 2005 NB I/II Cellular CN No Toxicity (surgery) 
Barrantes 1991 NB II Classic CN, RT Yes  Tumor progression 
Barrantes 1991 NB II Classic CN No Toxicity (surgery) 
Howell 1982 NB III NA CN (rupture), 
AMD 
No Toxicity (chemotherapy) 
Sandstedt 1985 NA NA NA NA No Toxicity (surgery) 
Sandstedt 1985 NA NA NA NA No Toxicity (surgery) 
Cook 1988 
/Malone 1989 
1d III NA CN (rupture), 
post-op CT 
No Toxicity (chemotherapy) 
Cook 1988 
/Malone 1989 
3d I/II NA CN No Toxicity (surgery) 
Case reports 
 
Ali 1994 NA NA Cellular CN Yes Tumor progression 
Cheol 2007 NB NA Cellular None No Tumor progression 
Jones 2007 1d III Cellular CN Yes  Tumor progression 
Joshi 1986 10m III Cellular CN, post-op CT 
(AVD), RT 
Yes  Tumor progression 
Santos 2011 2.8y NA Cellular CN, post-op CT  Yes Tumor progression 
Vujanic 1993 1.2y III Cellular Surgery, post-op 
CT (AV) 
Yes  Toxicity (chemotherapy) 
Angulo 1991 NB I Classic None No Stillborn (hydrops fetalis) 
Chen 2003 NB NA Classic None No Died directly after birth (hydrops 
fetalis) 
Anunobi 2014 NB NA Classic None No Died 13 hours after birth 
(prematurity, polyhydramnios 
mother) 
Correia 1995 7m I Classic CN No Toxicity (peritonitis due to 
peritoneal dialysis) 
Favara 1968 NB NA Classic None No Died 8 hours after birth (respiratory 
distress) 
Kumar 1985 0m NA Classic NA NA Toxicity (sepsis) 
Walker 1973 3m NA Classic CN, post-op CT 
(ACT) 
Yes  Tumor progression 
De Paepe 2011 NB NA Mixed None No Intra-uterine death (intra-tumoral 




NB NA Mixed CN Yes  Tumor progression 
Gray 1989 NB NA NA None No Intra-uterine death (hydrops fetalis) 
Kotani 2010 NB NA NA CN No Toxicity (surgery) 
Liu 1996 NB NA NA None No Died directly after birth (ascites, 
pleural effusions, pericardial 
effusion, subcutaneous oedema) 
Meenal 2003 NB NA NA None No Stillborn 
Blank 1978 NB NA NA CN No Toxicity (surgery) 
Bolande 1967 NB NA NA CN, post-op CT  
(ACT) 
No Toxicity (surgery) 
Larson 1978 NB NA NA None No Tumor progression and advanced 
hyaline membrane disease 
Wigger 1969 NB NA NA CN No Toxicity (surgery) 
Wigger 1969 NB NA NA CN No Toxicity (surgery) 
Abbreviations  CN: complete nephrectomy, NA: not available, NB: newborn, PN: partial nephrectomy, post-op CT: post-operative chemotherapy, 
pre-op CT: pre-operative chemotherapy, Tx: treatment 
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Supplemental Table S5. Characteristics, treatment and outcome of reported relapsed CMN patients 
Source Report Age Stage Histologic 
subtype 




Treatment of relapse Outcome (follow-up time) 
Series ≥ 10 
patients 
 
Furtwaengler 2006 3m III Cellular CN (rupture) NA Local S, CT (AVD) Alive (5.6y) 
Furtwaengler 2006 6m III Cellular PN, CN (rupture) NA Local CT (AVI) Died of tumor progression (1y) 
Furtwaengler 2006 2.7y I Cellular Pre-op CT, CN, post-op CT NA Local CT (ICED), RT, S Died of tumor progression (1.5y) 
Bayindir 2009 5m III Cellular Pre-op CT (AV), CN 
(incomplete), post-op CT (AV) 
2m Local S, CT (VCD/VP-16/IFO), RT Alive (7y) 
Chaudry 2009 NA NA Cellular CN <6m Local NA NA 
Chaudry 2009 NA NA Cellular CN <6m Local NA NA 
Watanabe 2007 1.1y II Cellular CN, post-op CT (NWTS-3 
regimen K) 
NA Bone (ilium, 
humerus, vertebrae) 
NA Died of tumor progression (1.3y) 
Anderson 2006 NB III Cellular CN 6m Local S, CT (VCR/IFO/ACT) Alive (NA) 
Barrantes 1991 NB II Classic CN, RT NA NA  None Died of tumor progression (9m) 
Bayindir 2009 3m II Mixed CN 6m Lung S, CT (VCD) Alive (4.5y) 
Anderson 2006 8m III Mixed CN 8m Local S, CT (AVD+ICE) Alive (NA) 
Howell 1982 4m NA NA CN (spill), AV 7m Local S, CT (DOX/CYC) Alive (1.6y) 
Case reports Ali 1994 NB NA Cellular CN 3m Local, brain S, CT (type NA) Died of tumor progression (9m) 
Jones 2007 NB III Cellular CN 6m Local S Alive (7m) 
Argani 2000 1.2y II Cellular S (type unknown) 12m Lung S Alive (7y) 
Glick 2004 3.5m II Cellular CN 6m Lung S, CT (type NA) Alive (6m) 
Gonzalez-Crussi 
1980 
7m NA Cellular CN 3m Lung S, RT, CT (ACT) Alive (5.5y) 
Jones 2007 1d III Cellular CN (rupture) 6m Local S, CT (AVD/CYC/CIS) Died of tumor progression (1.6y) 
Joshi 1986 10m III Cellular CN, post-op CT (AVD), RT 13m Local S, CT (AVD) Died of tumor progression (1.6y) 
Loeb 2002 1y III Cellular CN (rupture) 3m Local CT (AVD), RT Alive (18y) 
Loeb 2002 3m III Cellular CN (rupture), post-op CT (AVD) 5m Local CT (IFO/CARBO/VP-16), RT Alive (9y) 
Loeb 2002 NB III Cellular CN (rupture) 5m Local S, CT (VCD) Alive (2y) 
Patel 2003 9m II Cellular Pre-op CT (AV), CN 2.5m Liver CT (VCR/IFO/DOX/VP-16), S Alive (1.5y) 
Santos 2011 2.8y NA Cellular S (type unknown), post-op CT 
(type NA) 
8m Local S, CT (type NA) Died of tumor progression (1.2y) 
Steinfeld 1984 4m NA Cellular CN 2m Local, lung CT (AVD/CYC), RT, S Alive (1.6y) 
Vujanic 1993 1.2y III Cellular S (type unknown), post-op CT 
(AV) 
5m Lung, heart S, CT (IFO/VCR) Died of pneumonia (2y) 
Wang 2014 1.5m I Cellular TE 8m Local CT (AVD), S Alive (4y) 
Walker 1973 3m NA Classic CN, post-op CT (ACT) 4m Local S, RT Died of tumor progression (4m) 
Heidelberger 1993 NB NA Mixed CN 7m Brain S, CT (type NA) Died of tumor progression (14m) 
Ko 2013 NB III Mixed CN 7w Local, liver  CT (AVC) Alive (7m) 
Bell 2002 9m III Mixed Pre-op CT, PN, post-op CT 3m Liver S, CT (type NA) NA 
Joshi/Fu 1973 1d III NA CN 4m Local RT, CT (AV) Alive (15m) 
Abbreviations ACT: actinomycin, AVC: actinomycin/vincristine/cyclophosphamide, AVD: actinomycin/vincristine/doxorubicin, AVI: actinomycin/vincristine/ifosfamide, CIS: 
cisplatin, CN: complete nephrectomy, CT: chemotherapy, CYC: cyclophosphamide, DOX: doxorubicin, ICE: ifosfamide/carboplatin/etoposide, ICED: 
ifosfamide/cyclophosphamide/etoposide/doxorubicin, IFO: ifosfamide, m: months, NA: not available, NB: newborn, RT: radiotherapy, S: surgery, TE: tumor enucleation, VCD: 
vincristine/cyclophosphamide/doxorubicin, VCR: vincristine, VP-16: etoposide, y: years 
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Supplemental Table S6. Characteristics, treatment and outcome of reported stage III CMN patients  
Type of 
report 





Series ≥ 10 
patients 
Furtwaengler 2006 3m Female Cellular CN Tumor rupture Yes (local) Surgery, AVD Alive (5.6y) 





No - Alive (7.2y) 




Yes (local) AVI DOD (1y) 
Furtwaengler 2006 8m Female Cellular CN, 2nd look 
surgery, post-op CT 
Margin+, tumor 
rupture 
No - Alive (5.8y) 
Furtwaengler 2006 2y Female Cellular CN, post-op CT Margin+, tumor 
rupture 
No - Alive (1.9y) 
Bayindir 2009 
 
4m Female Cellular Biopsy, pre-op CT 
(AV), CN 
(incomplete), post-
op CT (AV) 












2m Male Cellular CN, post-op CT Margin+ No - Alive (2.5y) 
Bayindir 2009 3m Male Cellular Biopsy, pre-op CT Margin+ No - DOD (6m) 
England 2011 NB NA Cellular CN Margin+, tumor 
rupture 
No - Alive (4y) 
England 2011 2d NA Cellular CN Margin+ No - Alive (1.2y) 
Leclair 2005 NA NA Classic CN Tumor rupture No - Alive (2y) 
Furtwaengler 2006 NB Male Classic CN Margin+ No - Alive (2.2y) 
Furtwaengler 2006 1w Female Classic CN Margin+ No - Alive (2.7y) 
Furtwaengler 2006 2w Female Classic CN Margin+ No - Alive (2.4y) 
Furtwaengler 2006 3m Female Classic PN, 2nd look 
surgery, CN 
Margin+ No - Alive (1.1y) 
England 2011 7w NA Classic CN Margin+ No - Alive (5.3y) 
Anderson 2006 8m NA Mixed CN Tumor rupture Yes (local) Surgery. 
AVD+ICE 
Alive (NA) 
England 2011 1d NA Mixed CN Margin+ No - Alive (2.2y) 
England 2011 2d NA Mixed CN Margin+ No - Alive (2y) 
England 2011 11m NA Mixed CN, post-op CT Tumor rupture No - Alive (5.4y) 
Howell 1982 1d NA NA CN, post-op CT Margin+, tumor 
rupture 
No - Alive (2.5y) 
Howell 1982 2d NA NA CN, post-op CT Margin+, tumor 
rupture 
No - Alive (6.5y) 
Howell 1982 2d NA NA CN, post-op CT Tumor rupture No - Died of sepsis 
(2w) 
Howell 1982 3w NA NA CN Tumor rupture No - Alive (1.5y) 
Howell 1982 3w NA NA CN Tumor rupture No - Alive (1.7y) 
Howell 1982 1m NA NA CN Margin+, tumor 
rupture 
No - Alive (2.2y) 




No - Alive (2.5y) 
Howell 1982 4m NA NA CN, post-op CT Margin+, tumor 
rupture 
No - Alive (5.5y) 
Howell 1982 4m NA NA CN, post-op CT Margin+, tumor 
rupture 
Yes (local) Surgery, 
CYC/ADR 
Alive (2.2y) 
Howell 1982 5m NA NA CN, post-op CT Margin+ No -  
Howell 1982 16m NA NA CN, post-op CT, 
RT 
Margin+ No -  
Howell 1982 9y NA NA CN, post-op CT, 
RT 
Tumor rupture No -  
Cook 1988/Malone 
1989  




Jayabose 1988 2m Female Cellular CN, AVD Margin+ No - Alive (1.8y) 
Jones 2007 1d Female Cellular CN Margin+ Yes (local) Surgery, AVCD 
+ cisplatin 
DOD (1.5y) 
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Matsumara 1993 NB Male Cellular CN Tumor rupture No - Alive (2y) 
Jones 2007 NB Female Cellular CN Margin+ Yes (local) Surgery Alive (7m) 
Chan 1995 3d Female Cellular CN, VCR Surgical biopsy No - Alive (1y) 
Gormley 1989  2m Female Cellular CN, AV Tumor rupture No 0 Alive (9m) 
Kalidasan 1994  5m Male Cellular CN Tumor rupture No - Alive (7y) 
Kelly 1985  8m Female Cellular CN, AV Tumor rupture No - Alive (11m) 
Loeb 2002  12m Female Cellular CN Tumor rupture Yes (local) AVD, RT Alive (18y) 
Loeb 2002  3m Female Cellular CN, AVD Tumor rupture Yes (local) ICE, RT Alive (9y) 
Loeb 2002  NB Female Cellular CN Tumor rupture Yes (local) Surgery, VCD Alive (2y) 
McCahon 2003  NB Female Cellular AVC Surgical biopsy No - Alive (2.5y) 
Vujanic 1993  14m Female Cellular CN, AV Margin+ Yes (lungs, 
heart) 
Surgery, IV Died  of 
pneumonia (2y) 
Whittle 2010  NB Female Cellular CN Surgical biopsy No - Alive (1y) 
Irsutti 2000  NB Male Classic CN Margin+ No - Alive (10m) 
Walterhouse 1990  2d Male Classic CN Margin+ No - Alive (2y) 
Bell 2002  9m Female Mixed Pre-op CT, CN, 
post-op CT 
Margin+ Yes (liver) Surgery, CT 
(type unknown)  
 
Arensman 1980  4d Male NA CN Tumor rupture No - Alive (2y) 
Ehman 1983  NB Male NA CN Margin+ No - Alive (1y) 
Goldberg 1994 5m Male NA CN Tumor rupture No - Alive (1y) 
Joshi/Fu 1973  1d Female NA CN Margin+ Yes (local) Surgery, AV Alive (12.5y) 
Abbreviations  ADR: adriamycin, AV: actinomcyin/vincristine, AVC: actinomycin/vincristine/cyclophosphamide, AVCD: 
actinomycin/vincristine/cyclophosphamide/doxorubicin, AVD: actinomycin/vincristine/doxorubicin, CN: complete nephrectomy, CT: 
chemotherapy, CYC: cyclopohspahmide, DOD: died of disease (tumour progression), ICE: ifosfamide/carboplatin/etoposide, IV: 
ifosfamide/vincristine, NB: newborn, PN: partial nephrectomy, post-op CT: post-operative chemotherapy, pre-op CT: pre-operative 
chemotherapy, VCD: vincristine/cyclophosphamide/doxorubicin, VCR: vincristine, VIE: vincristine/ifosfamide/etoposide 
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